[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352260-105":59,"doc-detail-352260-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inhibition-of-her2-signaling-and-breast-cancer-cell-growth-with-a-novel-antibody-targeting-her2-ecd-iiiiv","Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV","","Human epidermal growth factor receptor 2 (HER2) is a key oncogenic driver across multiple solid tumors, while anti-HER2 therapies still face resistance and recurrence. Two novel HER2-targeting monoclonal antibodies, m66 and r40, were generated and tested for their ability to inhibit breast cancer cell proliferation in vitro. r40 more strongly suppresses PI3K/AKT and MAPK signaling than m66, and enhances the inhibition when combined with trastuzumab and pertuzumab. Cryo-EM structures show r40 binds HER2 ECD III/IV, supporting its therapeutic potential for HER2-positive breast cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inhibition-of-her2-signaling-and-breast-cancer-cell-growth-with-a-novel-antibody-targeting-her2-ecd-iiiiv/352260/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inhibition-of-her2-signaling-and-breast-cancer-cell-growth-with-a-novel-antibody-targeting-her2-ecd-iiiiv/352260.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in HER2-targeted breast cancer therapy?","Question",{"text":112,"@type":113},"Anti-HER2 treatments improve outcomes, but resistance and cancer recurrence remain major clinical challenges. The study aims to develop antibodies with complementary effects to existing therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the two novel antibodies, m66 and r40, differ in their biological effects?",{"text":117,"@type":113},"Both antibodies inhibit breast cancer cell proliferation in vitro, but r40 shows stronger suppression of the PI3K/AKT and MAPK signaling pathways compared with m66.",{"name":119,"@type":110,"acceptedAnswer":120},"What structural results explain how r40 may work in combination with existing drugs?",{"text":121,"@type":113},"Cryo-EM analyses identify that m66 recognizes an epitope overlapping with pertuzumab, while r40 binds within HER2 ECD III/IV, distinct from trastuzumab and pertuzumab binding sites. This distinct binding supports r40 as a promising combination candidate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352260,1790257675,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","OPEN ACCESS  \nCitation: Liu C, Ren Y, Luo X, Zhou P,  \nDu X, Wang Q, et al. (2026) Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV. PLoSOne 21(1): e0338127. [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0338127](journal.pone.0338127)  \nEditor: Irina V. Lebedeva, Weill Cornell Medicine, UNITED STATES OF AMERICA Received: March 15, 2025  \nAccepted: November 18, 2025  \nPublished: January 15, 2026  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0338127  \nCopyright: © 2026 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nInhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV  \nChunchun Liu1☯*, Yulei Ren1☯, Xuan Luo2,3☯, Peiyun Zhou1, Xiangjuan Du1,  \nQianmin Wang1, Xue Han1, Yanhui Xu1,4,5, Ping Wang6, Dan Zhao1,7*, Huirong Yang1,4,5*  \n1 Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Radiation Oncology, and Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College of Fudan University, Shanghai, China, 2 Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China, 3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 4 The International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Shanghai, China, 5 Department of Systems Biology for Medicine, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China, 6 Molinsights Biotechnologies, Guangdong Medical Valley Life Science Park, Guangzhou, China, 7 School of Life Sciences, Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University, Guangzhou, China  \n☯ These authors contributed equally to this work.  \n* [liuchun880616@yeah.net](liuchun880616@yeah.net) (CL); [danzhao5278@foxmail.com](danzhao5278@foxmail.com) (DZ); [yanghr@fudan.edu.cn](yanghr@fudan.edu.cn) (HY)  \nAbstract  \nHuman epidermal growth factor receptor 2 (HER2), a ligand-independent tyrosine kinase receptor belonging to the EGFR family, serves as a key oncogenic driver in breast, gastric, and several other solid tumors. Although anti-HER2 therapies have substantially improved survival outcomes—particularly in breast and gastric cancers—treatment resistance and cancer recurrence remain major clinical challenges. Thus, developing novel antibodies exhibiting complementary effects to the current anti-HER2 therapies could provide additional therapeutic benefits. Here, we describe two novel HER2-targeting monoclonal antibodies, m66 (murine-derived) and r40 (rabbit-derived), which inhibit breast cancer cell proliferation in vitro. Of the two, antibody r40 exhibits stronger suppression of the PI3K/AKT and MAPK signaling pathways compared to m66 . Moreover, the addition of r40 to the combination of trastuzumab and pertuzumab leads to a significantly enhanced inhibitory effect. We also determined the cryo-EM structures of the HER2-m66-trastuzumab ternary complex and the HER2-r40-trastuzumab-pertuzumab tetrameric complex, at overall resolutions of 3.2 Å and 3.1 Å, respectively. Structural analyses reveal that m66 recognizes an epitope overlapping with that of pertuzumab, whereas r40 binds within the HER2 ECD III/IV—a region distinct from the binding sites of both trastuzumab and pertuzumab. These findings identify r40 as a promis","cbCaivj49IJosztF","https://ap.wps.com/l/cbCaivj49IJosztF","pdf",1680986,"English","# Abstract\n## HER2 biology and therapeutic need\n## Novel antibody characterization (m66 and r40)\n## Signaling pathway inhibition and combination effects\n## Cryo-EM structural findings\n## Conclusions and therapeutic implications","[{\"question\":\"What problem does the study address in HER2-targeted breast cancer therapy?\",\"answer\":\"Anti-HER2 treatments improve outcomes, but resistance and cancer recurrence remain major clinical challenges. The study aims to develop antibodies with complementary effects to existing therapies.\"},{\"question\":\"How do the two novel antibodies, m66 and r40, differ in their biological effects?\",\"answer\":\"Both antibodies inhibit breast cancer cell proliferation in vitro, but r40 shows stronger suppression of the PI3K/AKT and MAPK signaling pathways compared with m66.\"},{\"question\":\"What structural results explain how r40 may work in combination with existing drugs?\",\"answer\":\"Cryo-EM analyses identify that m66 recognizes an epitope overlapping with pertuzumab, while r40 binds within HER2 ECD III/IV, distinct from trastuzumab and pertuzumab binding sites. This distinct binding supports r40 as a promising combination candidate.\"}]","Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV | PDF",1790098610,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59bcac096e82568d6289620b79e572ed.webp",983,1272,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1406263822374864cb97c70bbc927ab8.webp",982,1270,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4522ffb55ffaaeb428124df4b7cabbe2.webp",981,1269,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d2ba4dfd883e819b27e4fd7c28f752b.webp",980,1268]